Rigid gas permeable lens highly influences the interpretation of CXL results

Article

Wearing a rigid gas permeable lens can lead to improved topographic parameters and can significantly alter a number of study parameters.

Wearing a rigid gas permeable lens can lead to improved topographic parameters and can significantly alter a number of study parameters, claims a paper published in the British Journal of Ophthalmology.

A prospective, non-comparative study led by Dr Koppen Carina, Department of Ophthalmology, Antwerp University Hospital, Belgium, comprised of 15 eyes without rigid gas permeable contact lens (CL) and 12 eyes fitted with a CL from 1 to 10 weeks after ultraviolet A/riboflavin cross-linking (CXL) for the stabilisation of progressive keratoconus.

Refractive sphere and cylinder, maximal keratometry value (K max), simulated keratometry steep, flat, astigmatism, refractive power (RP) steep, flat and astigmatism, I-S value on EyeSys, K max on Pentacam and change from baseline of best spectacle-corrected visual acuity (BSCVA) were all used to measure the effect of CXL treatment on patients. The results of the study were recorded pre-CXL and in 6 month intervals for 18 months post-CXL.

There were no study parameters that demonstrated a significant change from baseline results in eyes without CL.

However, in eyes fitted with CL post-CXL I-S value and K max on EyeSys at all time intervals, RP steep and simulated astigmatism at 6 and 12 months and RP flat at 12 months all showed significant improvement.

CL can greatly influence the interpretation of CXL results, with lens wear improving topographic parameters.

Recent Videos
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
© 2025 MJH Life Sciences

All rights reserved.